Literature DB >> 28251889

Emergence of a novel subclade of influenza A(H3N2) virus in London, December 2016 to January 2017.

Heli Harvala1,2, Dan Frampton2, Paul Grant1, Jade Raffle2, Ruth Bridget Ferns2,3, Zisis Kozlakidis2, Paul Kellam4, Deenan Pillay2, Andrew Hayward5, Eleni Nastouli1,3,6.   

Abstract

We report the molecular investigations of a large influenza A(H3N2) outbreak, in a season characterised by sharp increase in influenza admissions since December 2016. Analysis of haemagglutinin (HA) sequences demonstrated co-circulation of multiple clades (3C.3a, 3C.2a and 3C.2a1). Most variants fell into a novel subclade (proposed as 3C.2a2); they possessed four unique amino acid substitutions in the HA protein and loss of a potential glycosylation site. These changes potentially modify the H3N2 strain antigenicity. This article is copyright of The Authors, 2017.

Entities:  

Keywords:  influenza; molecular; next generation sequencing; outbreak

Mesh:

Substances:

Year:  2017        PMID: 28251889      PMCID: PMC5356434          DOI: 10.2807/1560-7917.ES.2017.22.8.30466

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


The ongoing influenza season started early in eleven European Union countries, including England, on week 46 of 2016 [1]. The majority of reported infections have been caused by clade 3C.2a or 3C.2a1 influenza A(H3N2) viruses. The clade 3C.2a contains the current vaccine strain A/Hong Kong/4801/2014, and the first few viruses within the more recently emerged subclade 3C.2a1 were earlier shown to be antigenically matched with the vaccine component [2]. However, evidence for suboptimal vaccine effectiveness (VE) against laboratory-confirmed influenza A infection in people over 65 years-old was obtained in the first studies from Finland [3] and Sweden [4]. An outbreak of influenza A(H3N2) was first notified in our London centre on 30 December 2016. The outbreak coincided with unusually high ongoing circulation of respiratory syncytial virus (RSV) (Figure 1), and affected both patients and staff in the acute medical unit (AMU).
Figure 1

Percentage of positive respiratory samples for given viruses, and total number of respiratory samples tested per week, at the Department of Clinical Virology, University College of London Hospital, 19 September 2016–30 January 2017 (n=1,690 samples)

Percentage of positive respiratory samples for given viruses, and total number of respiratory samples tested per week, at the Department of Clinical Virology, University College of London Hospital, 19 September 2016–30 January 2017 (n=1,690 samples) Adeno: adenovirus; HMPV: human metapneumovirus; PIV: parainfluenza virus; RSV: respiratory syncytial virus. While infection control precautions were intensified, it resulted in multiple bay closures. We suspected that the sharp increase in the number of influenza A(H3N2) infections may have been caused by the emergence of a new genetic variant of H3N2, a hypothesis investigated through next generation sequencing (NGS) of influenza A(H3N2) strains.

Collection and analysis of respiratory samples

The main study was based on respiratory samples (n = 1,690) analysed at the Department of Virology, University College of London Hospital (UCLH), United Kingdom between 21 December 2016 and 24 January 2017. Most samples were collected as part of routine diagnostics from inpatients and patients seen at the Accident and Emergency department, and to a lesser extent from outpatients. The basic epidemiological data including patients’ age, admission and sampling dates as well as data on intensive care unit (ICU) admissions and deaths were collected. For comparison, results from influenza A and other virus testing from UCLH since 19 September 2016 were also analysed. The study was approved by the NRES Committee London, Surrey Borders HRA, (REC reference: 13/LO/1303). All samples were initially screened for influenza A virus by reverse transcription-PCR targeting the matrix gene. A total of 67 influenza A(H3N2) virus-positive samples obtained between 8 December 2016 and 3 January 2017 were sequenced. RNA was amplified using a modified eight-segment method [5]. Library preparations were generated as previously described [5,6]. A neighbour joining phylogenetic tree was constructed using Molecular Evolutionary Genetics Analysis (MEGA) 6 software [7]. Some sequences in the phylogenetic analysis were from the Global Initiative on Sharing All Influenza Data (GISAID); the authors gratefully acknowledge the 36 originating and submitting laboratories who contributed sequences to GISAID (www.gisaid.org).

Characteristics of the influenza A(H3N2) outbreak

Of the 1,690 respiratory samples obtained between 21 December 2016 and 24 January 2017, 352 samples were positive for influenza A(H3N2) virus (21%; Figure 1). Of those, 294 influenza A(H3N2)-positive samples had been obtained from 253 UCLH patients. Of patients with influenza A(H3N2) infection, over 50% (128/253) required hospital admission. An average of three inpatients (either existing inpatients or new admissions) were identified as influenza A(H3N2)-positive each day, and the highest number of hospital admissions was recorded on 10 January (n = 11; Figure 2a). Over the outbreak period, six patients required ICU admission and five died. Over a third of influenza A(H3N2) infections were seen in adults over 65 years-old (99/253; 39%), most of them admitted to hospital (72/99; 73%, Figure 2b).
Figure 2

Number (A) and age distribution (B) of influenza A(H3N2)-positive patients diagnosed at the University College of London Hospitals, 16 December 2016–24 January 2017 (n=253 patients)

Number (A) and age distribution (B) of influenza A(H3N2)-positive patients diagnosed at the University College of London Hospitals, 16 December 2016–24 January 2017 (n=253 patients)

Description of influenza A(H3N2) viruses circulating in London

Phylogenetic analyses of haemagglutinin (HA) sequences indicated co-circulation of variants from subclades of 3C.3a (n = 2), 3C.2a1 (n = 31) and 3C.2a (n = 34) (Figure 3).
Figure 3

Phylogenetic tree of the haemagglutinin gene sequences of virus strains recovered in this study using reference viruses for the different phylogenetic influenza A(H3N2)clades (n = 103 sequences)

Phylogenetic tree of the haemagglutinin gene sequences of virus strains recovered in this study using reference viruses for the different phylogenetic influenza A(H3N2)clades (n = 103 sequences) Bootstrap values obtained with 100 replicates are shown on some branches of the neighbour joining tree. The scale represents the percentage of nucleotide substitutions. Sequences are annotated in the following way: influenza type/geographical area of sample collection/sample number/year. For sequences previously characterised as belonging to the subclade 3C.2a, this is indicated after the year in parentheses. London sequences retrieved in this study are indicated with coloured circles (n = 67), and the vaccine strain with a black circle. The authors gratefully acknowledge the 36 originating and submitting laboratories who contributed sequences used in the phylogenetic analysis to the Global Initiative on Sharing All Influenza Data (GISAID; www.gisaid.org). Interestingly, our 3C.2a virus strains differed from the previously characterised subclade 3C.2a strains as well as from subclade 3C.2a1, and hence we have proposed them as a new subclade 3C.2a2. This subclade in turn split into two well defined but internally homogenous sub-clusters (cluster I and II; Figure 3), and also included all suspected outbreak cases admitted to AMU between 27 December 2016 and 3 January 2017 (n = 15). Individual clades of influenza A are typically defined by amino acid substitutions that occur as they diversify from parental strains. Such substitutions are potentially functionally relevant as they may influence the antigenicity and susceptibility to neutralising antibody induced by infection with other lineages of H3N2. Thus, investigated variants within the subclades 3C.2a and 3C.2a1 (n = 65) inherited amino acid substitutions known to define their parental clades (Figure 4). All variants within the proposed subclade 3C.2a2 shared two substitutions N121K and S144K, whereby S144K is an antigenic site flanking the receptor binding site (RBS). A further two additional substitutions were observed in each 3C.2a2 cluster (I58V and S219Y in cluster I and N122D and S262N in cluster II), all in the HA1 region and based on HA1 numbering. Cluster II viruses lost the potential N-linked glycosylation site (N122D).
Figure 4

Schematic diagram demonstrating the shared haemagglutinin (HA) amino acid changes between clades 3c, 3C.2, 3C.2a, 3C.2a1 and 3C.2a2 based on HA1 and HA2 numbering

Schematic diagram demonstrating the shared haemagglutinin (HA) amino acid changes between clades 3c, 3C.2, 3C.2a, 3C.2a1 and 3C.2a2 based on HA1 and HA2 numbering Changes in HA1 are indicated in normal font while changes in HA2 are in bold and italic. Changes in antigenic sites are shown with an asterisk (*) while changes resulting in the loss of a potential N-linked glycosylation site are underlined.

Discussion

In our centre in London, the early start and higher intensity of the 2016/17 influenza A(H3N2) virus epidemic mirrored that of the season 2014/15 where the subtype H3N2 also predominated. During the 2014/15 season, most influenza A(H3N2) infections in Europe were shown to be caused by antigenically drifted virus variants within the new genetic subgroup 3C.2a [8]. Our genetic analysis of London A(H3N2) viruses demonstrates ongoing co-circulation of drifted variants from multiple subclades (3C.3a, 3C.2a1 and proposed 3C.2a2). Four or more substitutions in two or more antibody binding sites are predicted to give an antigenically different virus [9] as in our case. Although we did not observe mutations in the seven positions suggested as being responsible for major transition clusters [10], position 144 is at the flank of the RBS, and additionally recognised as antigenic [11]. Although not necessarily determining major antigenic drift, the alterations of N-linked glycosylation sites are likely to contribute to more complex conformational changes in the HA due to gain or loss of glycosylation and can thus facilitate immune escape [12]. Furthermore, any amino acid changes in the 140–146 region of HA have been shown to be characteristic for antigenically distinct viruses of epidemic significance [9,13,14]. The amino acid substitution S144K in the emerging subclade 3C.2a2 viruses together with the loss of an N-linked glycosylation site (N122D) shows potential for antigenic drift that warrants further monitoring during this ongoing season. A limitation of our study was the lack of detailed vaccination data. Our findings in London of the rapid emergence of genetically drifted influenza A(H3N2) viruses underscore the potential for such strains to spread rapidly in hospital environments among patients and staff. Characterising emerging strains of influenza by next generation sequencing adds to the local and national monitoring of influenza trends. Further studies are needed to investigate the antigenic effects of substitutions occurring within the newly described subclade.
  9 in total

1.  MEGA6: Molecular Evolutionary Genetics Analysis version 6.0.

Authors:  Koichiro Tamura; Glen Stecher; Daniel Peterson; Alan Filipski; Sudhir Kumar
Journal:  Mol Biol Evol       Date:  2013-10-16       Impact factor: 16.240

Review 2.  Structural basis of immune recognition of influenza virus hemagglutinin.

Authors:  I A Wilson; N J Cox
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

3.  Haemagglutinin mutations and glycosylation changes shaped the 2012/13 influenza A(H3N2) epidemic, Houston, Texas.

Authors:  K M Stucker; S A Schobel; R J Olsen; H L Hodges; X Lin; R A Halpin; N Fedorova; T B Stockwell; A Tovchigrechko; S R Das; D E Wentworth; J M Musser
Journal:  Euro Surveill       Date:  2015-05-07

4.  Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation.

Authors:  D C Wiley; I A Wilson; J J Skehel
Journal:  Nature       Date:  1981-01-29       Impact factor: 49.962

5.  Evidence for N-glycan shielding of antigenic sites during evolution of human influenza A virus hemagglutinin.

Authors:  Yuki Kobayashi; Yoshiyuki Suzuki
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

6.  Structure and receptor binding preferences of recombinant human A(H3N2) virus hemagglutinins.

Authors:  Hua Yang; Paul J Carney; Jessie C Chang; Zhu Guo; Julie M Villanueva; James Stevens
Journal:  Virology       Date:  2015-01-22       Impact factor: 3.616

7.  Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution.

Authors:  Björn F Koel; David F Burke; Theo M Bestebroer; Stefan van der Vliet; Gerben C M Zondag; Gaby Vervaet; Eugene Skepner; Nicola S Lewis; Monique I J Spronken; Colin A Russell; Mikhail Y Eropkin; Aeron C Hurt; Ian G Barr; Jan C de Jong; Guus F Rimmelzwaan; Albert D M E Osterhaus; Ron A M Fouchier; Derek J Smith
Journal:  Science       Date:  2013-11-22       Impact factor: 47.728

8.  IVA: accurate de novo assembly of RNA virus genomes.

Authors:  Martin Hunt; Astrid Gall; Swee Hoe Ong; Jacqui Brener; Bridget Ferns; Philip Goulder; Eleni Nastouli; Jacqueline A Keane; Paul Kellam; Thomas D Otto
Journal:  Bioinformatics       Date:  2015-02-28       Impact factor: 6.937

9.  Viral population analysis and minority-variant detection using short read next-generation sequencing.

Authors:  Simon J Watson; Matthijs R A Welkers; Daniel P Depledge; Eve Coulter; Judith M Breuer; Menno D de Jong; Paul Kellam
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-04       Impact factor: 6.237

  9 in total
  21 in total

Review 1.  The Drift in Molecular Testing for Influenza: Mutations Affecting Assay Performance.

Authors:  Kathleen A Stellrecht
Journal:  J Clin Microbiol       Date:  2018-02-22       Impact factor: 5.948

Review 2.  Consolidation of Clinical Microbiology Laboratories and Introduction of Transformative Technologies.

Authors:  Zisis Kozlakidis; Alex van Belkum; Olivier Vandenberg; Géraldine Durand; Marie Hallin; Andreas Diefenbach; Vanya Gant; Patrick Murray
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

3.  Influenza A(H3N2) virus variants and patient characteristics during a summer influenza epidemic in Taiwan, 2017.

Authors:  Tsung-Pei Tsou; Chia-Ping Su; Wan-Ting Huang; Ji-Rong Yang; Ming-Tsan Liu
Journal:  Euro Surveill       Date:  2017-12

4.  Genetic and antigenic divergence in the influenza A(H3N2) virus circulating between 2016 and 2017 in Thailand.

Authors:  Nungruthai Suntronwong; Sirapa Klinfueng; Preeyaporn Vichiwattana; Sumeth Korkong; Thanunrat Thongmee; Sompong Vongpunsawad; Yong Poovorawan
Journal:  PLoS One       Date:  2017-12-18       Impact factor: 3.240

5.  Interim estimates of the effectiveness of the influenza vaccine against A(H3N2) influenza in adults in South Korea, 2016-2017 season.

Authors:  Ji Yun Noh; Sooyeon Lim; Joon Young Song; Won Suk Choi; Hye Won Jeong; Jung Yeon Heo; Jacob Lee; Yu Bin Seo; Jin-Soo Lee; Seong Heon Wie; Young Keun Kim; Kyung Hwa Park; Sook-In Jung; Shin Woo Kim; Sun Hee Lee; Han Sol Lee; Young Hoon Yoon; Hee Jin Cheong; Woo Joo Kim
Journal:  PLoS One       Date:  2017-05-25       Impact factor: 3.240

6.  Phylogenetic characterisation of circulating, clinical influenza isolates from Bali, Indonesia: preliminary report from the BaliMEI project.

Authors:  W Adisasmito; S N Budayanti; D N Aisyah; T Gallo Cassarino; J W Rudge; S J Watson; Z Kozlakidis; G J D Smith; R Coker
Journal:  BMC Infect Dis       Date:  2017-08-23       Impact factor: 3.090

7.  Characterization and Evolutionary Analysis of a Novel H3N2 Influenza A Virus Glycosylation Motif in Southern China.

Authors:  Zhiqi Zeng; Lee-Fong Yau; Zengxian Lin; Xuanzi Xia; Zifeng Yang; Jing-Rong Wang; Wenjun Song; Xinhua Wang
Journal:  Front Microbiol       Date:  2020-06-16       Impact factor: 5.640

8.  Genetic divergence of Influenza A(H3N2) amino acid substitutions mark the beginning of the 2016-2017 winter season in Israel.

Authors:  Aharona Glatman-Freedman; Yaron Drori; Sharon Alexandra Beni; Nehemya Friedman; Rakefet Pando; Hanna Sefty; Ilana Tal; John McCauley; Galia Rahav; Nathan Keller; Tamy Shohat; Ella Mendelson; Musa Hindiyeh; Michal Mandelboim
Journal:  J Clin Virol       Date:  2017-06-04       Impact factor: 3.168

9.  Influenza vaccine effectiveness in preventing hospitalisation of individuals 60 years of age and over with laboratory-confirmed influenza, Valencia Region, Spain, influenza season 2016/17.

Authors:  Ainara Mira-Iglesias; F Xavier López-Labrador; Beatriz Guglieri-López; Miguel Tortajada-Girbés; Víctor Baselga-Moreno; Laura Cano; Juan Mollar-Maseres; Mario Carballido-Fernández; Germán Schwarz-Chavarri; Javier Díez-Domingo; Joan Puig-Barberà
Journal:  Euro Surveill       Date:  2018-02

10.  Control of Infectious Diseases in the Era of European Clinical Microbiology Laboratory Consolidation: New Challenges and Opportunities for the Patient and for Public Health Surveillance.

Authors:  Olivier Vandenberg; Zisis Kozlakidis; Jacques Schrenzel; Marc Jean Struelens; Judith Breuer
Journal:  Front Med (Lausanne)       Date:  2018-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.